Infectious Diseases (except HIV/AIDS)
-
The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trial
This article has 73 authors:Reviewed by ScreenIT
-
Home Care Follow up determine the point of inversion of IL-6 levels in relation to C-Reactive Protein as the cytokine storm marker in COVID-19
This article has 14 authors:Reviewed by ScreenIT
-
Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis
This article has 16 authors:Reviewed by ScreenIT
-
Long-term symptoms after SARS-CoV-2 infection in a cohort of hospital employees: duration and predictive factors
This article has 7 authors:Reviewed by ScreenIT
-
Immunogenic superiority and safety of Biological E CORBEVAX vaccine compared to COVISHIELD (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial
This article has 22 authors:Reviewed by ScreenIT
-
Listening to Voices from African American Communities in the Southern States about COVID-19 Vaccine Information and Communication: A Qualitative Study
This article has 5 authors:Reviewed by ScreenIT
-
Evaluation of the Panbio COVID-19 Antigen Rapid Diagnostic Test in Subjects Infected with Omicron Using Different Specimens
This article has 18 authors:Reviewed by ScreenIT
-
Genomic Epidemiology of SARS-CoV-2 in Seychelles, 2020–2021
This article has 37 authors:Reviewed by ScreenIT
-
Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study
This article has 17 authors:Reviewed by ScreenIT
-
Fifteen-Month Follow-Up of Anti-Spike Receptor-Binding Domain SARS-CoV-2 Antibodies among Healthcare Workers in Boston, MA
This article has 5 authors:Reviewed by ScreenIT